A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques

Human monoclonal antibodies (mAbs) that target the spike glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) offer a promising approach for the prevention and treatment of coronavirus disease 2019 (COVID-19). Given suboptimal global vaccination rates, waning immunity in vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkolola, Joseph P., Yu, Jingyou, Wan, Huahua, Chang, Aiquan, McMahan, Katherine, Anioke, Tochi, Jacob-Dolan, Catherine, Powers, Olivia, Ye, Tianyi, Chandrashekar, Abishek, Sellers, Daniel, Barrett, Julia, Loo, Yueh-Ming, Esser, Mark T., Carnahan, Robert H., Crowe, James E., Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348747/
https://www.ncbi.nlm.nih.gov/pubmed/35857623
http://dx.doi.org/10.1126/scitranslmed.abo6160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348747/
https://www.ncbi.nlm.nih.gov/pubmed/35857623
http://dx.doi.org/10.1126/scitranslmed.abo6160

Ejemplares similares